The first results of using the combined drug rilpivirine/tenofovir/ emtricitabine in Russian patients with HIV infection in real clinical practice
- Authors: Sizova N.V1, Volova L.Y.2, Malyuzhenko I.V3, Isaeva G.N4, Koveleno A.Y.4, Minaeva S.V5,6, Topolskaya S.V7, Voronin E.E8, Okhonskaya L.V8
-
Affiliations:
- Center for Prevention and Control of AIDS and Communicable Diseases
- Yamal-Nenets District Center for AIDS Prevention and Control
- Volgograd Regional Center for Prevention and Control of AIDS and Communicable Diseases
- Leningrad Regional Center for Prevention and Control of AIDS and Communicable Diseases
- Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Communicable Diseases
- Nizhny Novgorod Medical Academy, Ministry of Health of Russia
- Clinical Center for AIDS Prevention and Control, Ministry of Health of the Krasnodar Territory
- Republican Clinical Hospital of Infectious Diseases of Ministry of Health of Russia
- Issue: No 6 (2015)
- Pages: 66-72
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278366
- ID: 278366
Cite item
Open Access
Access granted
Abstract
Objective. To evaluate the efficacy, safety, and tolerability of the combined drug rilpivirine/tenofovir/emtricitabine (RPV/TDF/FTC - еviplera) in Russian patients with a viral load (VL) of lower than 100 000 copies/ml. Subjects and methods. The data on 29 adult HIV-infected patients were analyzed. VH changes and CD4 + lymphocyte counts were estimated 6 months after initiation of RPV/TDF/FTC therapy and the pattern of blood laboratory values were assessed. Results. Six months after the therapy, 68.2% of the patients remained virologically suppressed; HIV RNA levels were decreased in 27.3% (the baseline VN was unsuppressed) and increased only in one patient. The median increase in CD4 + lymphocytes was 50.5 (0-535) cells/μl at 24 week. Adverse events and significant increases in hepatic enzymes and lipids were not observed; there was a slight decrease in the levels of total cholesterol, triglycerides, and glucose. Conclusion. Eviplera (RPV/TDF/FTC) combines a complete once-daily, single-tablet antiretroviral therapy regimen. The drug has demonstrated the high virologic and immunologic efficacy 6 months after treatment and no negative effect on liver function (also in HIV/HCV or HIV/HBV-coinfected patients), lipid profile, good tolerability profile, absence of CNS and gastrointestinal adverse reactions.
Full Text
About the authors
N. V Sizova
Center for Prevention and Control of AIDS and Communicable Diseases
Email: natalia_v_sizova@mail.ru
L. Yu Volova
Yamal-Nenets District Center for AIDS Prevention and Control
Email: volova_l@mail.ru
I. V Malyuzhenko
Volgograd Regional Center for Prevention and Control of AIDS and Communicable Diseases
Email: malyuzhenko@aidsvolgograd.ru
G. N Isaeva
Leningrad Regional Center for Prevention and Control of AIDS and Communicable Diseases
Email: G.N.Isaeva@yandex.ru
A. Yu Koveleno
Leningrad Regional Center for Prevention and Control of AIDS and Communicable Diseases
Email: Akovelenov@mail.ru
S. V Minaeva
Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Communicable Diseases; Nizhny Novgorod Medical Academy, Ministry of Health of Russia
Email: mistella@yandex.ru
S. V Topolskaya
Clinical Center for AIDS Prevention and Control, Ministry of Health of the Krasnodar Territory
Email: topolsv@mail.ru
E. E Voronin
Republican Clinical Hospital of Infectious Diseases of Ministry of Health of Russia
Email: evoronin1@rambler.ru
L. V Okhonskaya
Republican Clinical Hospital of Infectious Diseases of Ministry of Health of Russia
Email: lubasiklach@rambler.ru
References
- d'Arminio Monforte A., Lepri A.C., Rezza G., Pezzotti P., Antinori A., Phillips A.N., Angarano G., Colangeli V., De Luca A., Ippolito G., Caggese L., Soscia F., Filice G., Gritti F., Narciso P., Tirelli U., Moroni M. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 2000; 14(5): 499-507.
- Беляков Н.А., Захарова Н.Г., Сизовой Н.В. (ред.). Экономические и клинические вопросы ВИЧ-инфекции. Тематический архив. СПб: Балтийский медицинский образовательный центр, 2014. 210 с.
- Комарова И.В. Сердечно-сосудистый риск у ВИЧ-инфицированных пациентов. Автореф. дис.. канд. мед. наук. М., 2014.
- Dube M., Fenton M. Lipid abnormalities. Clin. Infect. Dis. 2003; 36(Suppl 2): S79- S83.
- Кравченко А.В., Ганкина Н.Ю., Канестри В.Г. Особенности антиретровирусной терапии у больных при сочетании ВИЧ-инфекции и хронического вирусного гепатита. Фарматека 2008; 19(173): 10-18.
- Канестри В.Г. Безопасность и переносимость современных схем антиретровирусной терапии у взрослых больных ВИЧ-инфекцией. Автореф. дис.. д-ра мед. наук. М., 2014.
- Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva, World Health Organization, 2013.
- Guidelines of European AIDS Clinical Society (version 7.1, 2014). http:// www.eacsociety.org/files/guidelines-7.1-russian.pdf
- BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012 (updated November 2013). http:// www.bhiva.org/HIV-1-treatment-guidelines.aspx
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (Last updated: April 8, 2015) http://www. aidsinfo.nih.gov/contentfiles/lvguidelines/AA_ Tables.pdf
- Мазус А.И., Каминский Г.Д., Зимина В.Н., Бессараб Т.П., Пронин А.Ю., Цыганова Е.В., Ольшанский А.Ю., Голохвастова Е.Л., Царенко С.П., Шимонова Т.Е., Петросян Т.Р., Халилулин Т.Р., Орлова-Морозова E.А., Серебряков Е.М., Набиуллина Д.Р., Иванова Т.В. Национальные клинические рекомендации по диагностике и лечению ВИЧ-инфекции у взрослых. M., 2014. 75 c.
- Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю., Ермак Т.Н., Буравцова Е.В., Шахгильдян В.И., Козырина Н.В., Нарсия Р.С., Зимина В.Н., Покровская А.В., Ефремова О.С. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2014; 6 (приложение).
- Cohen C., Bloch M., Wohl D., Arribas J., Henry K., Van Lunzen J., Towner W., Wilkins E., Garner W., Porter D., Temme L., Scharen-Guivel V., Bosse M., Rogatto F., Piontkowsky D. STaR study: single-tablet regimen rilpivirine/emtricitabine/tenofovir DF maintains noninferiority to efavirenz/emtricitabine/tenofovir DF in ART-naive adults through week 96 with a favourable safety profile for abnormal dreams and dizziness [poster no. WEPE064]. In: 20th International AIDS Conference. 20-25 Jul 2014, Melbourne. http://pag.aids2014.org/Abstracts. aspx?AID=9323
- Behrens G., Rijnders B., Nelson M., Orkin C., Cohen C., Mills A., Elion R., Vanveggel S., Stevens M., Rimsky L., Thorpe D., Bosse M., White K., Zhong L., DeMorin J., Chuck S. Rilpivirine versus efavirenz with emtricitabine/ tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA B100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS2014; 28(4): 168-175.
- Palella F. Jr., Fisher M., Tebas P., Gazzard B., Ruane P., van Lunzen J., Shamblaw D., Flamm J., Ebrahimi R., Porter D., White K., Hindman J., Elbert E., De-Oertel S., Fralich T. Simplification to rilpivirine/emtricitabine/ tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 2014; 28(3): 335-344.
- Emma D. Deeks Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Review of Its Use in HIV Infection. Drugs 2014; 74: 2079-2095.
- Bernardini C., Maggiolo F. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection. Patient Prefer Adherence. 2013; 7: 531-542.
- Куликов А.Ю., Бабий В.В. Фармакоэкономический анализ применения лекарственного средства эвиплера (рилпивирин/тенофовир/эмтрицитабин) для лечения ВИЧ-инфицированных пациентов на территории Российской Федерации. Фармакоэкономика. Теория и практика 2015; 3(1): 35-43.
Supplementary files
